Sanctuary Advisors LLC Makes New $138,000 Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Sanctuary Advisors LLC purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter, HoldingsChannel reports. The firm purchased 13,445 shares of the biopharmaceutical company’s stock, valued at approximately $138,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky grew its stake in shares of Amicus Therapeutics by 49.8% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 71,210 shares of the biopharmaceutical company’s stock valued at $706,000 after buying an additional 23,667 shares in the last quarter. Algert Global LLC acquired a new position in Amicus Therapeutics during the 2nd quarter worth about $879,000. The Manufacturers Life Insurance Company boosted its holdings in Amicus Therapeutics by 5.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 172,303 shares of the biopharmaceutical company’s stock valued at $1,709,000 after acquiring an additional 8,509 shares during the period. Millennium Management LLC grew its position in Amicus Therapeutics by 1,758.9% in the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after acquiring an additional 1,792,277 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C increased its stake in Amicus Therapeutics by 80.4% during the second quarter. Deerfield Management Company L.P. Series C now owns 29,752 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 13,263 shares during the period.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,168,002.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 22,500 shares of company stock worth $244,875 over the last three months. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on FOLD. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research report on Friday, September 20th. Morgan Stanley reduced their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. lowered their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $12.01 on Tuesday. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The firm has a market capitalization of $3.56 billion, a PE ratio of -24.51 and a beta of 0.69. The business’s fifty day moving average price is $11.17 and its 200 day moving average price is $10.55.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same period in the prior year, the firm posted ($0.15) EPS. The business’s quarterly revenue was up 34.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.07 earnings per share for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.